Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
Atossa Therapeutics, Inc. logo

NASDAQ · ATOS

Atossa Therapeutics, Inc.

Healthcare · Biotechnology

$2.30

Up+$0.13 (+5.99%)

Updated Nov 3, 2026, 3:19 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
116.87M
P/E ratio
-4.07
Dividend yield
0.00%
52-week range
$1.70 – $14.85
Volume
66.3K
Avg. volume
872.57K

Price performance · ATOS

ATOS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ATOS closed at $2.30 after 21 trading sessions, down 6.12% for the selected period.

Last close
$2.30
Period change
-6.12%
Period low
$2.17
Period high
$2.91
Daily close
View OHLC price history
ATOS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$2.21$2.40$2.205$2.3066.3K
Oct 30, 2026$2.25$2.43$2.14$2.1732.9K
Oct 29, 2026$2.35$2.375$2.22$2.2368.01K
Oct 28, 2026$2.38$2.425$2.36$2.3729.46K
Oct 27, 2026$2.44$2.628$2.37$2.3824.83K
Oct 26, 2026$2.58$2.58$2.40$2.4535.08K
Oct 23, 2026$2.74$2.85$2.60$2.6077.02K
Oct 22, 2026$2.49$2.77$2.46$2.7290.66K
Oct 21, 2026$2.53$2.585$2.38$2.53189.63K
Oct 20, 2026$2.54$2.67$2.51$2.5436.76K
Oct 19, 2026$2.66$2.76$2.51$2.5680.52K
Oct 16, 2026$2.59$2.95$2.51$2.91104.63K
Oct 15, 2026$2.78$3.12$2.53$2.65227.03K
Oct 14, 2026$2.52$2.81$2.4501$2.78238.71K
Oct 13, 2026$2.35$2.60$2.30$2.5671.41K
Oct 12, 2026$2.44$2.53$2.335$2.388781.42K
Oct 9, 2026$2.45$2.74$2.12$2.44265.61K
Oct 8, 2026$2.46$2.478$2.385$2.42101.01K
Oct 7, 2026$2.41$2.49$2.41$2.4619.07K
Oct 6, 2026$2.46$2.54$2.43$2.4554.63K
Oct 5, 2026$2.38$2.4999$2.341$2.4553.32K

Latest ATOS news

The latest Smart Investors Daily articles mentioning ATOS.

Stock researchCompany · Overview

ATOS research

Overview

Company profile and research snapshot.

Company profile

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
ATOS recent ratings
DateFirmRatingTarget
Oct 1, 2026Ascendiant CapitalBuy—
Jul 7, 2026Rodman & RenshawBuy—
Apr 10, 2026Ascendiant CapitalBuy—
Mar 26, 2026HC Wainwright & Co.Buy—
Dec 8, 2025Ascendiant CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today confirmed that each outstanding share of Atossa common stock will begin trading with one stapled contingent value right ("CVR") as of the close of business today, October 19, 2026.

Yahoo · Oct 9, 2026

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, today announced that it has entered into a definitive Stapled Contingent Value Rights Agreement (the "CVR Agreement") with VStock Transfer, LLC, as rights agent, implementing the stapled contingent value rights ("CVRs") plan previously announced on September 29, 2026.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By